Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline’s new Ebola vaccine shows benefits in early study

GlaxoSmithKline’s new Ebola vaccine shows benefits in early study

28th November 2014

GlaxoSmithKline has published early-stage clinical trial data that demonstrates the potential safety and efficacy of its new Ebola vaccine candidate.

Developed in partnership with the US National Institutes of Health, the vaccine has been tested in a small phase I trial and was shown to be well-tolerated, producing an immunological response in each of the 20 healthy adult volunteers in the US who received it.

The therapy uses a type of chimpanzee cold virus as a carrier to deliver genetic material from two strains of the Ebola virus, the Sudan strain and the Zaire strain, with the latter being responsible for the current outbreak in west Africa.

Following this, the next phases of the clinical trial programme will begin in early 2015, with phase III studies to involve the vaccination of thousands of volunteers, including frontline healthcare workers in affected countries.

Dr Moncef Slaoui, chairman of global vaccines at GlaxoSmithKline, said: "We are very encouraged by these positive first trial results showing this type of vaccine has an acceptable safety profile and can produce an immune response against Ebola in humans."

The company has been working with a number of global partners, including the World Health Organization, to accelerate the development of the vaccine as much as possible.ADNFCR-8000103-ID-801763079-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.